COSTEM 2019 | Post-transplant cyclophosphamide mechanisms

Christopher Kanakry

Christopher Kanakry, MD, Center for Cancer Research, National Cancer Institute, Bethesda, MD, discusses optimizing timing of post-transplantation cyclophosphamide in MHC-haploidentical murine hematopoietic cell transplantation (HSCT). This interview was recorded at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

Share this video  
Similar topics